WATCHLONGEVITY

Sunday, June 21, 2026

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Importance
62
Trust
60
Urgency
30
REGULATORY · PRIMARY SOURCE

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

The FDA warned patients and doctors about risks from unapproved weight-loss drugs like semaglutide and tirzepatide made by compounding pharmacies. The agency found problems with storage, fake products, wrong doses, and counterfeit versions that could harm patients.

Analysis

FDA flagged fake and badly dosed compounded semaglutide and tirzepatide. This pushes patients toward brand-name Ozempic and Zepbound, hurting compounding-dependent sellers.

  • As of July 31, 2025, FDA received 605 adverse event reports for compounded semaglutide
  • As of July 31, 2025, FDA received 545 adverse event reports for compounded tirzepatide
  • Retatrutide and cagrilintide cannot be used in compounding under federal law
$NVO$LLY$HIMS
semaglutidetirzepatideretatrutidecagrilintide
FDA Drug Approvals & Databases25d
Read
BREAKING
Importance
72
Trust
71
Urgency
95
CLINICAL TRIAL

Novo Nordisk halts clinical development of CagriSema variant - medwatch.com

Novo Nordisk stopped testing a version of CagriSema, a peptide drug being developed for weight loss and diabetes. The company did not explain why it halted the clinical trial.

Analysis

Novo's next big weight-loss drug just lost a version in testing. That hurts its push to catch Lilly in the obesity drug race.

  • Novo Nordisk stopped clinical development of a CagriSema variant
  • CagriSema is being developed for weight loss and diabetes
  • Novo did not say why it halted the trial
$NVO
cagrilintideNovo Nordisk
Novo Nordisk News1mo
Read
DEVELOPING
Importance
55
Trust
71
Urgency
65
COMMERCIAL

‘No change’ for CagriSema as Novo ditches single-chamber device - Fierce Biotech

Novo Nordisk is dropping a single-chamber injection device for CagriSema, a two-drug weight-loss shot combining cagrilintide and semaglutide. The company says the change won't affect when CagriSema reaches patients.

Analysis

Novo dropped a one-shot device for its new weight-loss drug CagriSema. The company says patients will still get the drug on time.

  • Novo Nordisk dropped the single-chamber injection device for CagriSema
  • CagriSema combines cagrilintide and semaglutide for weight loss
  • Novo says the device change will not delay CagriSema's launch timeline
$NVO
cagrilintidesemaglutidecagrisemaNovo Nordisk
FierceBiotech1mo
Read